Cobalt-Catalyzed Reductive Alkylation of Heteroaryl Bromides: One-Pot Access to Alkylthiophenes, -furans, -selenophenes, and -pyrroles
作者:Deng-Jhou Cai、Po-Han Lin、Ching-Yuan Liu
DOI:10.1002/ejoc.201500784
日期:2015.8
A practical and convenient Co-catalyzed alkylation method for the facile introduction of various alkyl chains into organic electronically significant heteroaryl compounds, including thiophenes, furans, selenophenes, and pyrroles, is reported. Under well-optimized reaction conditions, a wide range of alkylated heteroaryl compounds have beeen efficiently prepared in moderate to good isolated yields.
OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS
申请人:Prosensa Technologies B.V.
公开号:EP2870246A2
公开(公告)日:2015-05-13
Oligonucleotide for the Treatment of Muscular Dystrophy Patients
申请人:Prosensa Technologies B.V.
公开号:US20150191725A1
公开(公告)日:2015-07-09
The invention relates to an oligonucleotide and to a pharmaceutical composition comprising said oligonucleotide. This oligonucleotide is able to bind to a region of a first exon from a dystrophin pre-mRNA and to a region of a second exon within the same pre-mRNA, wherein said region of said second exon has at least 50% identity with said region of said first exon, wherein said oligonucleotide is suitable for the skipping of said first and second exons of said pre-mRNA, and preferably the entire stretch of exons in between.
NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS
申请人:The Scripps Research Institute
公开号:US20170050941A1
公开(公告)日:2017-02-23
Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.
[EN] OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS<br/>[FR] OLIGONUCLÉOTIDE POUR LE TRAITEMENT DE PATIENTS ATTEINTS DE DYSTROPHIE MUSCULAIRE
申请人:PROSENSA TECHNOLOGIES BV
公开号:WO2014007620A2
公开(公告)日:2014-01-09
The invention relates to an oligonucleotide and to a pharmaceutical composition comprising said oligonucleotide. This oligonucleotide is able to bind to a region of a first exon from a dystrophin pre-mRNA and to a region of a second exon within the same pre-mRNA, wherein said region of said second exon has at least 50% identity with said region of said first exon, wherein said oligonucleotide is suitable for the skipping of said first and second exons of said pre-mRNA, and preferably the entire stretch of exons in between.